Your browser doesn't support javascript.
loading
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Merryman, Reid W; Carreau, Nicole A; Advani, Ranjana H; Spinner, Michael A; Herrera, Alex F; Chen, Robert; Tomassetti, Sarah; Ramchandren, Radhakrishnan; Hamid, Muhammad; Assouline, Sarit; Santiago, Raoul; Wagner-Johnston, Nina; Paul, Suman; Svoboda, Jakub; Bair, Steven M; Barta, Stefan K; Liu, Yang; Nathan, Sunita; Karmali, Reem; Burkart, Madelyn; Torka, Pallawi; David, Kevin A; Wei, Catherine; Lansigan, Frederick; Emery, Lukas; Persky, Daniel; Smith, Sonali M; Godfrey, James; Chavez, Julio; Cohen, Jonathan B; Troxel, Andrea B; Diefenbach, Catherine; Armand, Philippe.
Afiliação
  • Merryman RW; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Carreau NA; NY Cancer and Blood Specialists, New York, New York, USA.
  • Advani RH; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
  • Spinner MA; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
  • Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Chen R; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Tomassetti S; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Ramchandren R; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Hamid M; Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Assouline S; Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • Santiago R; Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • Wagner-Johnston N; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
  • Paul S; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
  • Svoboda J; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Bair SM; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Barta SK; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Liu Y; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Nathan S; Rush University Medical Center, Chicago, Illinois, USA.
  • Karmali R; Division of Hematology, Northwestern University, Chicago, Illinois, USA.
  • Burkart M; Northwestern Memorial Hospital, Chicago, Illinois, USA.
  • Torka P; Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • David KA; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Wei C; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Lansigan F; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Emery L; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Persky D; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, Arizona, USA.
  • Smith SM; University of Chicago, Chicago, Illinois, USA.
  • Godfrey J; University of Chicago, Chicago, Illinois, USA.
  • Chavez J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Cohen JB; Emory University Winship Cancer Institute, Atlanta, Georgia, USA.
  • Troxel AB; Perlmutter Cancer Center, New York University School of Medicine, New York, New York, USA.
  • Diefenbach C; Perlmutter Cancer Center, New York University School of Medicine, New York, New York, USA.
  • Armand P; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Oncologist ; 25(6): e993-e997, 2020 06.
Article em En | MEDLINE | ID: mdl-32275786
ABSTRACT
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Inibidores de Checkpoint Imunológico Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Inibidores de Checkpoint Imunológico Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos